Bayer HealthCare Pharmaceuticals in Richmond, California

Bayer HealthCare Pharmaceuticals' U.S. research center focuses on biotechnology and is presently located on a 53-acre campus in Richmond. Overlooking the San Francisco Bay, this location is ideal for recruiting new talent and collaborating with public or private institutions. Researchers here work to identify novel protein therapeutics and apply new scientific knowledge to improve two key Bayer biotechnology products — Betaseron^® and Kogenate^® — and advance new products in various indications with special emphasis on hemophilia and multiple sclerosis.

Bayer's research team works with scientists at the Berkeley campus, scientists who develop processes to manufacture complex biologics at clinical and commercial scale. This process science team works from a $100 million new clinical manufacturing center on the Bayer Berkeley campus. In addition to working on novel therapeutics discovered by Bayer internally, this team collaborates with Titan Pharmaceuticals on the development of one of the most advanced cell therapies, Spheramine, which is a product candidate presently in Phase 2 clinical study on Parkinson's Disease.

It's important to note that in the Bay Area, Bayer's R&D infrastructure includes a team of clinicians based in Berkeley who oversee clinical studies to improve the lives of individuals with hemophilia.

2600 Hilltop Drive
Richmond, California 94806
(510) 262-5000

* BETASERON^® (Interferon beta-1b) is indicated for the treatment of relapsing forms of multiple sclerosis to reduce the frequency of clinical exacerbations. Patients with multiple sclerosis in whom efficacy has been demonstrated include patients who have experienced a first clinical episode and have MRI features consistent with multiple sclerosis.

Important Safety Information
The most commonly reported adverse reactions are lymphopenia, injection-site reaction, asthenia, flu-like symptom complex, headache and pain. Gradual dose titration and use of analgesics during treatment initiation may help reduce flu-like symptoms. BETASERON should be used with caution in patients with depression. Injection-site necrosis has been reported in 4% of patients in controlled trials. Patients should be advised of the importance of rotating injection sites. Female patients should be warned about the potential risk to pregnancy. Cases of anaphylaxis have been reported rarely. See "Warnings," "Precautions," and "Adverse Reactions" sections of full Prescribing Information.

* Kogenate^® FS Antihemophilic Factor (Recombinant), is a recombinant Factor VIII treatment indicated for the treatment of hemophilia A. The most frequently reported adverse events were local injection site reactions, dizziness and rash. Known intolerance or allergic reactions to constituents of the preparation is a contraindication to the use of Kogenate^® FS. Known hypersensitivity to mouse or hamster protein may be a contraindication to the use of Kogenate^® FS. For important safety and use information, please see the full prescribing information.

* Product information is intended for U.S. Audiences Only